We are live on ! Find out more
CNST

Constellation Pharmaceuticals, Inc.
CNST

Delisted

CNST was delisted on the 14th of July, 2021.

Back to rankings

50 hedge funds and large institutions have $204M invested in Constellation Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

14% more funds holding

Funds holding: 44 → 50 (+6)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

9% less capital invested

Capital invested by funds: $225M → $204M (-$21M)

Holders
50
Holders Change
+6
Holders Change %
+13.64%
% of All Funds
1.09%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
12
Increased
12
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.9M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.39M
3
PAWC
P.A.W. Capital
Connecticut
+$1.34M
4
BlackRock
BlackRock
New York
+$1.05M
5
State Street
State Street
Massachusetts
+$839K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.22M
2
First Eagle Investment Management
First Eagle Investment Management
New York
-$1.07M
3
EIM
Essex Investment Management
Massachusetts
-$897K
4
DM
Deerfield Management
New York
-$777K
5
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$678K
Name Holding Trade Value Shares
Change 		Change in
Stake
PS
1
Peter Svennilson
$57.4M – – –
TG
2
TRV GP
Massachusetts
$37.3M – – –
CC
3
Casdin Capital
New York
$18.7M -$368K -33,039 -2%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$16.9M -$2.22M -199,781 -13%
CAM
5
Cormorant Asset Management
Massachusetts
$15.6M -$22 -2 -0%
O
6
OrbiMed
New York
$10.3M – – –
BlackRock
7
BlackRock
New York
$10.1M +$1.05M +94,107 +13%
VMI
8
VHCP Management II
New York
$8.92M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$6.51M +$1.39M +124,591 +31%
HIM
10
Hillhouse Investment Management
Cayman Islands
$3.9M – – –
State Street
11
State Street
Massachusetts
$3.11M +$839K +75,389 +42%
DM
12
Deerfield Management
New York
$2.25M -$777K -69,800 -28%
Northern Trust
13
Northern Trust
Illinois
$1.8M +$184K +16,548 +13%
BBA
14
Baker Bros. Advisors
New York
$1.64M – – –
PAWC
15
P.A.W. Capital
Connecticut
$1.47M +$1.34M +120,000 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.29M +$174K +15,647 +17%
VMI
17
VHCP Management III
New York
$819K – – –
JRP
18
Jasper Ridge Partners
California
$757K – – –
AA
19
ALPS Advisors
Colorado
$663K +$601K +54,000 New
N
20
Nuveen
North Carolina
$504K +$457K +41,050 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$446K -$20.9K -1,880 -5%
Charles Schwab
22
Charles Schwab
California
$397K – – –
First Eagle Investment Management
23
First Eagle Investment Management
New York
$350K -$1.07M -96,536 -77%
BCM
24
Bridgeway Capital Management
Texas
$338K – – –
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$329K +$298K +26,801 New
1
2 3

CNST Hedge Fund Activity: Q2 2019 in Review

50 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q2 2019, worth a combined $204M — down 9.3% from $225M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CNST positions and 5 closed out — a net gain of 7 holders — while 12 added to existing stakes and 13 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $3.9M. The largest seller was Fidelity Investments, cutting an estimated $2.22M.

  • 50 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q2 2019, up from 44 in Q1 2019.
  • Funds reported $204M of Constellation Pharmaceuticals, Inc. stock for Q2 2019, down 9.3% quarter-over-quarter.
  • 12 funds opened new Constellation Pharmaceuticals, Inc. positions in Q2 2019 and 5 closed out, a net change of +7 holders.
  • The largest Constellation Pharmaceuticals, Inc. buyer in Q2 2019 was T. Rowe Price Associates, an estimated $3.9M added.
  • The largest Constellation Pharmaceuticals, Inc. seller in Q2 2019 was Fidelity Investments, an estimated $2.22M sold.

Based on aggregated 13F filings for Q2 2019.